[1] Mohd HK,Groeger J,Flaxman AD,et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology, 2013, 57: 1333-1342.
[2] 陈红松,窦晓光,段钟平,等. 丙型肝炎防治指南(2015年更新版). 临床肝胆病杂志, 2015, 31: 1961-1979.
[3] Jacobson IM,Dore GJ,Foster GR,et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3,randomised,double-blind,placebo-controlled trial. Lancet, 2014, 384: 403-413.
[4] Herbst DA,Reddy KR. Sofosbuvir,a nucleotide polymerase inhibitor,for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs, 2013, 22: 527-536.
[5] Lawitz E,Mangia A,Wyles D,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med, 2013, 368: 1878-1887.
[6] Jacobson IM,Gordon SC,Kowdley KV,et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med, 2013, 368: 1867-1877.
[7] Belema M,Nguyen VN,Bachand C,et al. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem, 2014, 57: 2013-2032.
[8] Sulkowski MS,Gardiner DF,Rodriguez-Torres M,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med, 2014, 370: 211-221.
[9] Nelson DR,Cooper JN,Lalezari JP,et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology, 2015, 61: 1127-1135.
[10] Leroy V,Angus P,Bronowicki JP,et al. Daclatasvir,sofosbuvir,and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology, 2016, 63: 1430-1441.
[11] 张秀春,李红,王健. 索菲布韦联合达卡他韦及利巴韦林治疗丙型肝炎肝硬化疗效观察. 中国药物与临床, 2016, 16: 1188-1191.
[12] Boglione L,Pinna SM,Cardellino CS,et al. Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. Infection, 2017, 45: 103-106.
[13] Poordad F,Schiff ER,Vierling JM,et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology, 2016, 63: 1493-1505.
[14] Wyles DL,Ruane PJ,Sulkowski MS,et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med, 2015, 373: 714-725.
[15] Rockstroh JK,Ingiliz P,Petersen J,et al. Daclatasvir plus sofosbuvir,with or without ribavirin,in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir Ther, 2017, 22: 225-236. |
